对患者的方法 - 骨质疏松症治疗中的转变
Bente L Langdahl1,2, Natasha A Laursen1,2, Vivi Mäkinen1,2
1Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
The Journal of clinical endocrinology and metabolism
|November 17, 2025
概括
过渡性骨质疏松症治疗需要仔细规划. 虽然大多数药物切换是安全的,但要避免从抗吸收剂转换为骨类合成药物,或在没有后续检查的情况下停止使用德诺苏马布,以保持治疗的有效性.
科学领域:
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨质疏松症的管理需要顺序的治疗策略.
- 有效的骨质疏松症治疗包括优化治疗过渡.
- 目标导向治疗需要了解治疗顺序的好处和风险.
研究的目的:
- 评估骨质疏松症治疗过渡的机会和挑战.
- 确定骨质疏松症的安全有效的顺序治疗策略.
- 关于骨质疏松症药物测序的临床决策信息.
主要方法:
- 关于骨质疏松症治疗过渡的现有文献的审查.
- 分析骨矿物质密度 (BMD) 和抗骨折功效数据.
- 对各种处理序列的安全性概况的评估.
主要成果:
- 从骨代谢剂过渡到抗吸收剂可以保持BMD的增长和抗骨折效应.
- 在抗吸收药物之间切换,特别是对内药物,如佐莱德酸盐或德诺苏马布,可以进一步增加BMD.
- 从抗吸收剂过渡到骨类合成药物可能会削弱合成效应.
- 在2-3年后停止服用德诺苏马布会带来挑战.
结论:
- 顺序性骨质疏松症治疗对于预防骨折和实现最佳的骨质疏松症至关重要.
- 大多数骨质疏松症治疗过渡都是安全和有益的.
- 由于潜在的麻木效应和风险,避免从德诺苏马布过渡到骨类合成药物或在没有随后治疗的情况下停止服用德诺苏马布.
相关概念视频
Bone Disorders
5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Bone Remodeling
40.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.2K
Osteoclasts in Bone Remodeling
3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
Drug Administration and Therapy Phases: Overview
1.2K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.2K
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180

